The FIGHT DMD Trial is a 12-month, double-blind, placebo-controlled study to evaluate the effectiveness and safety of oral ifetroban in participants with Duchenne muscular dystrophy.

DMD Heart Disease

DMD is commonly diagnosed in childhood, when kids start missing major milestones such as crawling or walking. As the disease progresses, the heart, which is also a muscle, will weaken as well. The purpose of this trial is to evaluate the safety and effectiveness of a novel targeted therapy, ifetroban, in the treatment of DMD heart disease, an unmet medical need.

boxing-kid-cut200.jpg

Purpose of the FIGHT Trial

Fibrosis is the process of replacing normal tissue with scarred tissue which cannot function like normal tissue. Scarring of the heart is part of the disease process in Duchenne. Ifetroban is being studied as a potential anti-fibrotic medication in several diseases but is not approved for and has never been studied in DMD patients. Studies in animal models of DMD showed oral ifetroban can prevent the scarring in the heart associated with Duchenne and improve survival compared to placebo. You can read more about these studies here.